Quantcast

U.S. Market for Neurostimulation Devices Will Reach Almost $4 Billion by 2022

April 9, 2014

New Indications and Demand for Replacement Devices Will Drive Market Expansion, According to Findings from Decision Resources Group

BURLINGTON, Mass., April 9, 2014 /PRNewswire/ — Decision Resources Group finds that the approval of new indications–particularly chronic heart failure, obesity and epilepsy–will expand the patient pool and market potential for neurostimulation devices in the United States considerably, allowing the market to reach a value approaching $4 billion by 2022. Most notably, because neurostimulation is already well accepted as a treatment for epilepsy, the Food and Drug Administration’s (FDA) approval in 2013 of NeuroPace’s deep brain stimulation (DBS) device for this indication will lead to rapid adoption of this product.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the Medtech 360 report entitled US Markets for Neurostimulation Devices 2014:

    --  Replacement devices: Demand for replacement of implantable pulse
        generators will drive market expansion. Through 2022, many devices that
        were implanted in first-time patients will reach the end of their life
        spans, and replacement devices will be required.
    --  Complex reimbursement process: Although reimbursement is available for
        most indications, the approval process for eligible patients is
        extensive and complex; the process carries high up-front costs in some
        cases and can be so lengthy that some patients decide to forgo this
        treatment altogether.
    --  Alternative treatments: Due to the invasive nature of neurostimulation
        therapy, some patients will also prefer alternative treatments such as
        lifestyle and medical management for most indications where feasible.
    --  Market leader Medtronic: Medtronic holds more than half of the overall
        revenues in this market. The company has a first-mover advantage and has
        thus far maintained its monopoly in the DBS, sacral nerve stimulation
        and gastric electric stimulation device segments.

Comments from Decision Resources Group Analyst Roald Dhoska:

    --  "Many companies are attempting to enter the U.S. neurostimulation device
        market to capitalize on strong revenue growth. Boston Scientific is
        seeking FDA approval of its DBS system, Nevro Corp and Spinal Modulation
        are both running clinical trials for spinal cord stimulation products
        and numerous competitors are racing to capitalize on the market
        potential by expanding indications in the vagus nerve stimulation
        segment."
    --  "Penetration into the eligible patient populations for most devices is
        low because many referring physicians are not exposed to
        neurostimulation in medical school. New manufacturers looking to enter
        the market will be well positioned for success if they can implement
        educational campaigns that target these physicians."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus